OUR CLINICAL TRIALS - Amgen Oncology

1 OUR CLINICAL TRIALS . ANTIBODY DRUG CONJUGATE (ADC). AMG 224 (ADC). Research Area Description Phase Status NCT/ Amgen ID*. Multiple First-in-Human Study of AMG 224 in Relapsed 02561962. Myeloma or Refractory Multiple Myeloma 1 R 20130314. APOPTOSIS. AMG 232 (MDM2 inhibitor). Research Area Description Phase Status NCT/ Amgen ID*. AMG 232 in Combination With Trametinib in 02016729. Leukemia 1b Relapsed/Refractory Acute Myeloid Leukemia 20120234. AMG 232 Combined With Trametinib 02110355. Melanoma 1b/2a +/- Debrafenib in Metastatic Melanoma 20120238. Solid Tumors A Phase 1 Study Evaluating AMG 232 in 01723020. and Multiple 1. Myeloma Advanced Solid Tumors or Multiple Myeloma 20120106.

2 AMG 176 (MCL-1 inhibitor). Research Area Description Phase Status NCT/ Amgen ID*. Multiple First-in-Human Study of AMG 176 in Relapsed or 02675452. 1. Myeloma Refractory Multiple Myeloma 20150161. BIOSIMILARS. ABP 215 (Biosimilar bevacizumab; VEGF inhibitor). Research Area Description Phase Status NCT/ Amgen ID*. Efficacy and Safety Study of ABP 215 Compared 01966003. NSCLC With Bevacizumab in Subjects With Advanced 3 C 20120265. Non-Small Cell Lung Cancer ABP 980 (Biosimilar trastuzumab; HER2 receptor inhibitor). Research Area Description Phase Status NCT/ Amgen ID*. Efficacy and Safety Study of ABP 980 01901146. Breast Compared With Trastuzumab in Subjects With 3 A 20120283.

3 HER2-Positive Early Breast Cancer Active, recruiting Active, not recruiting Completed, pending results BONE METASTASES AND METABOLISM. Denosumab (RANK-ligand inhibitor). Research Area Description Phase Status NCT/ Amgen ID*. Denosumab as Adjuvant Treatment for Women 01077154. Breast With High Risk Early Breast Cancer Receiving 3. 20060359. Neoadjuvant or Adjuvant Therapy (D-CARE). Giant Cell Denosumab in Subjects With Giant Cell 00680992. 2. Tumor Tumor of Bone 20062004. Denosumab Compared to Zoledronic Acid in Multiple 01345019. the Treatment of Bone Disease in Subjects With 3. Myeloma 20090482. Multiple Myeloma Denosumab in Combination With Chemotherapy 01951586. NSCLC 2.

4 As First-line Treatment of Metastatic NSCLC 20120249. Osteonecrosis 01666106. Osteonecrosis of the Jaw Case Registry N/A. of the Jaw 20101102. A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic 00925600 . Prostate 3. Prostate Cancer Receiving Denosumab for Bone 20080560. Loss Due to Androgen-Deprivation Therapy HEMATOPOIESIS. Darbepoetin alfa (erythropoiesis-stimulating agent). Research Area Description Phase Status NCT/ Amgen ID*. Darbepoetin alfa for the Treatment of Anemic 01362140. MDS 3. Subjects With Low or Intermediate-1 Risk MDS 20090160. Anemia Treatment for Advanced NSCLC 00858364 . NSCLC 3. Patients Receiving Chemotherapy 20070782.

5 Pegfilgrastim (granulocyte colony-stimulating factor). Research Area Description Phase Status NCT/ Amgen ID . Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary 02178475. Breast, NHL N/A. Prophylaxis in Breast Cancer and NHL Patients 20120214. Receiving High (>20%) FN-risk Chemotherapy Romiplostim (thrombopoiesis stimulator). Research Area Description Phase Status NCT/ Amgen ID*. Long-term Dosing of Romiplostim in 01071954. 3. Thrombocytopenic Pediatric Subjects With ITP 20090340. ITP. Single Arm, Open-label, Long-term Study of 02279173. Romiplostim in Thrombocytopenic Pediatric 3. 20101221. Subjects With ITP IMMUNOTHERAPY. AMG 211 (Bispecific T-Cell Engager Antibody Construct: anti-CD3 + anti-CEA).

6 Research Area Description Phase Status NCT/ Amgen ID*. Safety and Efficacy of AMG 211 in Adult 02291614. Gastrointestinal Subjects With Advanced Gastrointestinal 1. 20130354. Adenocarcinoma AMG 228 (GITR protein agonist). Research Area Description Phase Status NCT/ Amgen ID*. First-in-Human Study of AMG 228 in Adult 02437916. Solid Tumors 1. Subjects With Advanced Solid Tumors 20140131. AMG 330 (Bispecific T-Cell Engager Antibody Construct: anti-CD3 + anti-CD33). Research Area Description Phase Status NCT/ Amgen ID*. Acute First-In-Human Study of AMG 330 in Adult 02520427. Myeloid Subjects With Relapsed/Refractory Acute Myeloid 1. 20120252. Leukemia Leukemia Blinatumomab (Bispecific T-Cell Engager Antibody Construct: anti-CD3 + anti-CD19).

7 Research Area Description Phase Status NCT/ Amgen ID*. Study of Blinatumomab in Japanese Adults With 02412306. 1/2. Relapsed/Refractory B-precursor ALL 20130265. 02000427. Blinatumomab in Philadelphia-positive ALL 2. 20120216. Expanded Access Protocol of Blinatumomab 02187354. Leukemia in Pediatric and Adolescent Subjects With N/A Available 20130320. Relapsed and/or Refractory B-precursor ALL. Trial of Blinatumomab vs Investigator's Choice 02013167. of Chemotherapy in Patients With Relapsed or 3. 103311. Refractory ALL. Trial of Blinatumomab vs Standard 02393859. Chemotherapy in Pediatric Subjects With 3. 20120215. High Risk First Relapse B-precursor ALL. Active, recruiting Active, not recruiting Completed, pending results IMMUNOTHERAPY, continued Talimogene Laherparepvec (oncolytic immunotherapy).

8 Research Area Description Phase Status NCT/ Amgen ID*. Talimogene Laherparepvec With Pembrolizumab Head and 02626000. for Recurrent Metastatic Squamous Cell 1b Neck 20130232. Carcinoma of the Head and Neck Ipilimumab With or Without Talimogene 01740297. 1b/2. Laherparepvec in Unresected Melanoma 20110264. Efficacy and Safety of Talimogene Laherparepvec 02211131. Neoadjuvant Treatment Plus Surgery Versus 2. 20110266. Surgery Alone for Melanoma Single-arm Trial to Evaluate the Biodistribution 02014441. 2. and Shedding of Talimogene Laherparepvec 20120324. Single-arm Trial to Evaluate the Role of the 02366195. Immune Response to Talimogene Laherparepvec 2. Melanoma 20120325.

9 In Unresected Melanoma Expanded Access Study of Talimogene 02297529. Laherparepvec for Treatment of Subjects With 3b Available 20120328. Unresected Stage IIIB-IVM1c Melanoma Pembrolizumab With or Without Talimogene 02263508. 3. Laherparepvec in Unresected Melanoma 20110265. 02173171. Registry Study for Talimogene Laherparepvec N/A. 20120139. Safety Study of Talimogene Laheraprepvec 02509507. Solid Tumors Injected Into Hepatocellular Carcinoma and 1. 20140318. Metastatic Liver Tumors Active, recruiting Active, not recruiting Completed, pending results PROTEIN DEGRADATION. Carfilzomib (proteasome inhibitor). Research Area Description Phase Status NCT/ Amgen ID*. Hematologic Pharmacokinetics and Safety of Carfilzomib in 01949545.

10 Malignancies, Subjects With Advanced Malignancies 1 C CFZ002. Solid Tumors and Varying Degrees of Hepatic Impairment Carfilzomib in Combination With Dexamethasone, 02303821. Leukemia Mitoxantrone, PEG-asparaginase, and Vincristine 1/2. CFZ008. in Children With Relapsed or Refractory ALL. Pharmacokinetics and Safety of Carfilzomib 01949532. in Subjects With Multiple Myeloma and 1. CFZ001. Renal Disease Study of Carfilzomib Administered Once 02335983. Weekly in Combination With Lenalidomide 1b CFZ013. and Dexamethasone in Multiple Myeloma CHAMPION 2: Study of Carfilzomib, 01980589. Cyclophosphamide and Dexamethasone in 1b 2012-003. Newly Diagnosed Multiple Myeloma Subjects Multiple CHAMPION 1: Weekly Carfilzomib in Myeloma 01677858.